modelIndium111inOxinateLabell
Extends from Pharmacolibrary.Drugs.ATC.V.V09HB01.
Information
| name: | Indium111inOxinateLabelledCells | |
| ATC code: | V09HB01 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 4.5 | L |
| clearance: | 0.18 | L/h |
| other parameters in model implementation | ||
Indium (111In) oxinate labelled cells are used primarily for radiolabeling autologous leukocytes for diagnostic imaging, especially in infection or inflammation localization (e.g., detection of abscesses and osteomyelitis). The radiopharmaceutical is approved and widely used in nuclear medicine for such imaging applications.
Pharmacokinetics
Pharmacokinetic parameters relate to healthy adult volunteers and patients undergoing nuclear medicine imaging for infection/inflammation. Pharmacokinetics reflect labeled cell distribution rather than a classical drug.
References
Maghazachi, AA, & Fitzgibbon, L (1990). Fate of intravenously administered rat lymphokine-activated killer cells labeled with different markers. Cancer immunology, immunotherapy : CII 31(3) 139–145. DOI:10.1007/BF01744727 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2337903
Melder, RJ, et al., & Jain, RK (2002). Systemic distribution and tumor localization of adoptively transferred lymphocytes in mice: comparison with physiologically based pharmacokinetic model. Neoplasia (New York, N.Y.) 4(1) 3–8. DOI:10.1038/sj.neo.7900209 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11922388
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)